The biology of TRAIL and the role of TRAIL-based therapeutics in infectious diseases

Anti-Infective Agents in Medicinal Chemistry

Volumn 8, Issue 2, 2009, Pages 87-101

  Shepard, Brett D ^a   Badley, Andrew D ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; LEXATUMUMAB; MAPATUMUMAB; PROTEIN ANTIBODY; PROTEIN BCL 2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BINDING AFFINITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG RECEPTOR BINDING; FATIGUE; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; KIDNEY FAILURE; LIVER DISEASE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MYALGIA; NONHODGKIN LYMPHOMA; NONHUMAN; SEPSIS; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSAMINITIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VIRUS LOAD;

EID: 67651099147     PISSN: 18715214     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152109787846060     Document Type: Article

References (181)

1. Duiker, E. W.; Mom, C. H.; de Jong, S.; Willemse, P. H.; Gietema, J. A.; van der Zee, A. G.; de Vries, E. G. The clinical trail of TRAIL. Eur. J. Cancer, 2006, 42, 2233-40.
2. Di Pietro, R.; Zauli, G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J. Cell. Physiol., 2004, 201, 331-40.
3. Li, H.; Zhu, H.; Xu, C. J.; Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 1998, 94, 491-501.
4. Luo, X.; Budihardjo, I.; Zou, H.; Slaughter, C.; Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 1998, 94, 481-90.
5. Spierings, D. C.; de Vries, E. G.; Vellenga, E.; van den Heuvel, F. A.; Koornstra, J. J.; Wesseling, J.; Hollema, H.; de Jong, S. Tissue distribution of the death ligand TRAIL and its receptors. J. Histochem. Cytochem., 2004, 52, 821-31.
6. Wiley, S. R.; Schooley, K.; Smolak, P. J.; Din, W. S.; Huang, C. P.; Nicholl, J. K.; Sutherland, G. R.; Smith, T. D.; Rauch, C.; Smith, C. A.; et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3, 673-82.
7. Sedger, L. M.; Shows, D. M.; Blanton, R. A.; Peschon, J. J.; Goodwin, R. G.; Cosman, D.; Wiley, S. R. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J. Immunol., 1999, 163, 920-6.
8. Ashkenazi, A.; Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol., 1999, 11, 255-60.
9. Gura, T. How TRAIL kills cancer cells, but not normal cells. Science, 1997, 277, 768.
10. Pan, G.; Ni, J.; Wei, Y. F.; Yu, G.; Gentz, R.; Dixit, V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 1997, 277, 815-8.
11. Nitsch, R.; Bechmann, I.; Deisz, R. A.; Haas, D.; Lehmann, T. N.; Wendling, U.; Zipp, F. Human brain-cell death induced by tumournecrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet, 2000, 356, 827-8.
12. Jo, M.; Kim, T. H.; Seol, D. W.; Esplen, J. E.; Dorko, K.; Billiar, T. R.; Strom, S. C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med., 2000, 6, 564-7.
13. Mori, E.; Thomas, M.; Motoki, K.; Nakazawa, K.; Tahara, T.; Tomizuka, K.; Ishida, I.; Kataoka, S. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell. Death Differ., 2004, 11, 203-7.
14. Schaefer, U.; Voloshanenko, O.; Willen, D.; Walczak, H. TRAIL: a multifunctional cytokine. Front. Biosci., 2007, 12, 3813-24.
15. Chaudhari, B. R.; Murphy, R. F.; Agrawal, D. K. Following the TRAIL to apoptosis. Immunol. Res., 2006, 35, 249-62.
16. Kayagaki, N.; Yamaguchi, N.; Nakayama, M.; Eto, H.; Okumura, K.; Yagita, H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med., 1999, 189, 1451-60.
17. Ehrlich, S.; Infante-Duarte, C.; Seeger, B.; Zipp, F. Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine, 2003, 24, 244-53.
18. Kemp, T. J.; Elzey, B. D.; Griffith, T. S. Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/ Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J. Immunol., 2003, 171, 212-8.
19. Liu, S.; Yu, Y.; Zhang, M.; Wang, W.; Cao, X. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J. Immunol., 2001, 166, 5407-15.
20. Takeda, K.; Smyth, M. J.; Cretney, E.; Hayakawa, Y.; Yamaguchi, N.; Yagita, H.; Okumura, K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell. Immunol., 2001, 214, 194-200.
21. Johnsen, A. C.; Haux, J.; Steinkjer, B.; Nonstad, U.; Egeberg, K.; Sundan, A.; Ashkenazi, A.; Espevik, T. Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine, 1999, 11, 664-72.
22. Kashii, Y.; Giorda, R.; Herberman, R. B.; Whiteside, T. L.; Vujanovic, N. L. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J. Immunol., 1999, 163, 5358-66.
23. Halaas, O.; Vik, R.; Ashkenazi, A.; Espevik, T. Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand. J. Immunol., 2000, 51, 244-50.
24. Saitou, Y.; Shiraki, K.; Fuke, H.; Inoue, T.; Miyashita, K.; Yamanaka, Y.; Yamaguchi, Y.; Yamamoto, N.; Ito, K.; Sugimoto, K.; Nakano, T. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases. Hum. Pathol., 2005, 36, 1066-73.
25. Mundt, B.; Kuhnel, F.; Zender, L.; Paul, Y.; Tillmann, H.; Trautwein, C.; Manns, M. P.; Kubicka, S. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J., 2003, 17, 94-6.
26. Smyth, M. J.; Takeda, K.; Hayakawa, Y.; Peschon, J. J.; van den Brink, M. R.; Yagita, H. Nature's TRAIL - on a path to cancer immunotherapy. Immunity, 2003, 18, 1-6.
27. Ashkenazi, A.; Dixit, V. M. Death receptors: signaling and modulation. Science, 1998, 281, 1305-8.
28. Kimberley, F. C.; Screaton, G. R. Following a TRAIL: update on a ligand and its five receptors. Cell Res., 2004, 14, 359-72.
29. Pan, G.; O'Rourke, K.; Chinnaiyan, A. M.; Gentz, R.; Ebner, R.; Ni, J.; Dixit, V. M. The receptor for the cytotoxic ligand TRAIL. Science, 1997, 276, 111-3.
30. Screaton, G. R.; Mongkolsapaya, J.; Xu, X. N.; Cowper, A. E.; McMichael, A. J.; Bell, J. I. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol., 1997, 7, 693-6.
31. Walczak, H.; Degli-Esposti, M. A.; Johnson, R. S.; Smolak, P. J.; Waugh, J. Y.; Boiani, N.; Timour, M. S.; Gerhart, M. J.; Schooley, K. A.; Smith, C. A.; Goodwin, R. G.; Rauch, C. T. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J., 1997, 16, 5386-97.
32. Wu, G. S.; Burns, T. F.; McDonald, E. R., 3rd; Jiang, W.; Meng, R.; Krantz, I. D.; Kao, G.; Gan, D. D.; Zhou, J. Y.; Muschel, R.; Hamilton, S. R.; Spinner, N. B.; Markowitz, S.; Wu, G.; el-Deiry, W. S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet., 1997, 17, 141-3.
33. Sheridan, J. P.; Marsters, S. A.; Pitti, R. M.; Gurney, A.; Skubatch, M.; Baldwin, D.; Ramakrishnan, L.; Gray, C. L.; Baker, K.; Wood, W. I.; Goddard, A. D.; Godowski, P.; Ashkenazi, A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 1997, 277, 818-21.
34. Falschlehner, C.; Emmerich, C. H.; Gerlach, B.; Walczak, H. TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol., 2007, 39, 1462-75.
35. LeBlanc, H. N.; Ashkenazi, A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ., 2003, 10, 66-75.
36. MacFarlane, M.; Ahmad, M.; Srinivasula, S. M.; Fernandes-Alnemri, T.; Cohen, G. M.; Alnemri, E. S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem., 1997, 272, 25417-20.
37. Emery, J. G.; McDonnell, P.; Burke, M. B.; Deen, K. C.; Lyn, S.; Silverman, C.; Dul, E.; Appelbaum, E. R.; Eichman, C.; DiPrinzio, R.; Dodds, R. A.; James, I. E.; Rosenberg, M.; Lee, J. C.; Young, P. R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem., 1998, 273, 14363-7.
38. Truneh, A.; Sharma, S.; Silverman, C.; Khandekar, S.; Reddy, M. P.; Deen, K. C.; McLaughlin, M. M.; Srinivasula, S. M.; Livi, G. P.; Marshall, L. A.; Alnemri, E. S.; Williams, W. V.; Doyle, M. L. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem., 2000, 275, 23319-25.
39. Griffith, T. S.; Rauch, C. T.; Smolak, P. J.; Waugh, J. Y.; Boiani, N.; Lynch, D. H.; Smith, C. A.; Goodwin, R. G.; Kubin, M. Z. Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol., 1999, 162, 2597-605.
40. Griffith, T. S.; Chin, W. A.; Jackson, G. C.; Lynch, D. H.; Kubin, M. Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol., 1998, 161, 2833-40.
41. Cretney, E.; Shanker, A.; Yagita, H.; Smyth, M. J.; Sayers, T. J. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol. Cell Biol., 2006, 84, 87-98.
42. Strater, J.; Walczak, H.; Pukrop, T.; Von Muller, L.; Hasel, C.; Kornmann, M.; Mertens, T.; Moller, P. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology, 2002, 122, 659-66.
43. Janssen, H. L.; Higuchi, H.; Abdulkarim, A.; Gores, G. J. Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J. Hepatol., 2003, 39, 414-20.
44. Fiorucci, G.; Vannucchi, S.; Chiantore, M. V.; Percario, Z. A.; Affabris, E.; Romeo, G. TNF-related apoptosis-inducing ligand (TRAIL) as a pro-apoptotic signal transducer with cancer therapeutic potential. Curr. Pharm. Des., 2005, 11, 933-44.
45. Suliman, A.; Lam, A.; Datta, R.; Srivastava, R. K. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene, 2001, 20, 2122-33.
46. Deveraux, Q. L.; Takahashi, R.; Salvesen, G. S.; Reed, J. C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature, 1997, 388, 300-4.
47. Roy, N.; Deveraux, Q. L.; Takahashi, R.; Salvesen, G. S.; Reed, J. C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J., 1997, 16, 6914-25.
48. Vogler, M.; Durr, K.; Jovanovic, M.; Debatin, K. M.; Fulda, S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene, 2007, 26, 248-57.
49. Verhagen, A. M.; Ekert, P. G.; Pakusch, M.; Silke, J.; Connolly, L. M.; Reid, G. E.; Moritz, R. L.; Simpson, R. J.; Vaux, D. L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell, 2000, 102, 43-53.
50. Deng, Y.; Lin, Y.; Wu, X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev, 2002, 16, 33-45.
51. Fulda, S.; Wick, W.; Weller, M.; Debatin, K. M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med., 2002, 8, 808-15.
52. Li, L.; Thomas, R. M.; Suzuki, H.; De Brabander, J. K.; Wang, X.; Harran, P. G. A small molecule Smac mimic potentiates TRAIL-and TNFalpha-mediated cell death. Science, 2004, 305, 1471-4.
53. Golks, A.; Brenner, D.; Fritsch, C.; Krammer, P. H.; Lavrik, I. N. c-FLIPR, a new regulator of death receptor-induced apoptosis. J. Biol. Chem., 2005, 280, 14507-13.
54. Krueger, A.; Schmitz, I.; Baumann, S.; Krammer, P. H.; Kirchhoff, S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem., 2001, 276, 20633-40.
55. Koschny, R.; Walczak, H.; Ganten, T. M. The promise of TRAIL-potential and risks of a novel anticancer therapy. J. Mol. Med., 2007, 85, 923-35.
56. Bodmer, J. L.; Holler, N.; Reynard, S.; Vinciguerra, P.; Schneider, P.; Juo, P.; Blenis, J.; Tschopp, J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell. Biol., 2000, 2, 241-3.
57. Kischkel, F. C.; Lawrence, D. A.; Chuntharapai, A.; Schow, P.; Kim, K. J.; Ashkenazi, A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity, 2000, 12, 611-20.
58. Sprick, M. R.; Weigand, M. A.; Rieser, E.; Rauch, C. T.; Juo, P.; Blenis, J.; Krammer, P. H.; Walczak, H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity, 2000, 12, 599-609.
59. Kischkel, F. C.; Lawrence, D. A.; Tinel, A.; LeBlanc, H.; Virmani, A.; Schow, P.; Gazdar, A.; Blenis, J.; Arnott, D.; Ashkenazi, A. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem., 2001, 276, 46639-46.
60. Muzio, M.; Stockwell, B. R.; Stennicke, H. R.; Salvesen, G. S.; Dixit, V. M. An induced proximity model for caspase-8 activation. J. Biol. Chem., 1998, 273, 2926-30.
61. Salvesen, G. S.; Dixit, V. M. Caspase activation: the inducedproximity model. Proc. Natl. Acad. Sci. USA, 1999, 96, 10964-7.
62. Shi, Y. Caspase activation: revisiting the induced proximity model. Cell, 2004, 117, 855-8.
63. Chao, Y.; Shiozaki, E. N.; Srinivasula, S. M.; Rigotti, D. J.; Fairman, R.; Shi, Y. Engineering a dimeric caspase-9: a re-evaluation of the induced proximity model for caspase activation. PLoS Biol., 2005, 3, e183.
64. Cohen, G. M. Caspases: the executioners of apoptosis. Biochem. J., 1997, 326, 1-16.
65. Khosravi-Far, R.; Esposti, M. D. Death receptor signals to mitochondria. Cancer Biol. Ther., 2004, 3, 1051-7.
66. Sprick, M. R.; Walczak, H. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim. Biophys. Acta, 2004, 1644, 125-32.
67. Mayes, P. A.; El-Deiry, W. S. The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. Cancer J., 2006, 12, 247-9.
68. Bouillet, P.; Strasser, A. BH3-only proteins - evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. J. Cell Sci., 2002, 115, 1567-74.
69. Cheng, E. H.; Wei, M. C.; Weiler, S.; Flavell, R. A.; Mak, T. W.; Lindsten, T.; Korsmeyer, S. J. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell, 2001, 8, 705-11.
70. Nagata, S. Apoptosis by death factor. Cell, 1997, 88, 355-65.
71. Walczak, H.; Miller, R. E.; Ariail, K.; Gliniak, B.; Griffith, T. S.; Kubin, M.; Chin, W.; Jones, J.; Woodward, A.; Le, T.; Smith, C.; Smolak, P.; Goodwin, R. G.; Rauch, C. T.; Schuh, J. C.; Lynch, D. H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med., 1999, 5, 157-63.
72. Takeda, K.; Smyth, M. J.; Cretney, E.; Hayakawa, Y.; Kayagaki, N.; Yagita, H.; Okumura, K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med., 2002, 195, 161-9.
73. Seki, N.; Hayakawa, Y.; Brooks, A. D.; Wine, J.; Wiltrout, R. H.; Yagita, H.; Tanner, J. E.; Smyth, M. J.; Sayers, T. J. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res., 2003, 63, 207-13.
74. Cretney, E.; Takeda, K.; Yagita, H.; Glaccum, M.; Peschon, J. J.; Smyth, M. J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol., 2002, 168, 1356-61.
75. Sedger, L. M.; Glaccum, M. B.; Schuh, J. C.; Kanaly, S. T.; Williamson, E.; Kayagaki, N.; Yun, T.; Smolak, P.; Le, T.; Goodwin, R.; Gliniak, B. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol., 2002, 32, 2246-54.
76. Wu, G. S.; Burns, T. F.; Zhan, Y.; Alnemri, E. S.; El-Deiry, W. S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosisinducing ligand (TRAIL) death receptor. Cancer Res., 1999, 59, 2770-5.
77. Yue, H. H.; Diehl, G. E.; Winoto, A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ., 2005, 12, 94-7.
78. Zerafa, N.; Westwood, J. A.; Cretney, E.; Mitchell, S.; Waring, P.; Iezzi, M.; Smyth, M. J. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol., 2005, 175, 5586-90.
79. Lamhamedi-Cherradi, S. E.; Zheng, S.; Tisch, R. M.; Chen, Y. H. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes, 2003, 52, 2274-8.
80. Lamhamedi-Cherradi, S. E.; Zheng, S. J.; Maguschak, K. A.; Peschon, J.; Chen, Y. H. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat. Immunol., 2003, 4, 255-60.
81. Mi, Q. S.; Ly, D.; Lamhamedi-Cherradi, S. E.; Salojin, K. V.; Zhou, L.; Grattan, M.; Meagher, C.; Zucker, P.; Chen, Y. H.; Nagle, J.; Taub, D.; Delovitch, T. L. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes, 2003, 52, 1967-75.
82. Cretney, E.; Uldrich, A. P.; Berzins, S. P.; Strasser, A.; Godfrey, D. I.; Smyth, M. J. Normal thymocyte negative selection in TRAIL-deficient mice. J. Exp. Med., 2003, 198, 491-6.
83. Simon, A. K.; Williams, O.; Mongkolsapaya, J.; Jin, B.; Xu, X. N.; Walczak, H.; Screaton, G. R. Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proc. Natl. Acad. Sci. USA, 2001, 98, 5158-63.
84. Diehl, G. E.; Yue, H. H.; Hsieh, K.; Kuang, A. A.; Ho, M.; Morici, L. A.; Lenz, L. L.; Cado, D.; Riley, L. W.; Winoto, A. TRAIL-R as a negative regulator of innate immune cell responses. Immunity, 2004, 21, 877-89.
85. Newton, K.; Harris, A. W.; Bath, M. L.; Smith, K. G.; Strasser, A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J., 1998, 17, 706-18.
86. Cretney, E.; McQualter, J. L.; Kayagaki, N.; Yagita, H.; Bernard, C. C.; Grewal, I. S.; Ashkenazi, A.; Smyth, M. J. TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol. Cell. Biol., 2005, 83, 511-9.
87. Hilliard, B.; Wilmen, A.; Seidel, C.; Liu, T. S.; Goke, R.; Chen, Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol., 2001, 166, 1314-9.
88. Aktas, O.; Smorodchenko, A.; Brocke, S.; Infante-Duarte, C.; Schulze Topphoff, U.; Vogt, J.; Prozorovski, T.; Meier, S.; Osmanova, V.; Pohl, E.; Bechmann, I.; Nitsch, R.; Zipp, F. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron, 2005, 46, 421-32.
89. Gong, B.; Almasan, A. Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem. Biophys. Res. Commun., 2000, 278, 747-52.
90. Sato, K.; Hida, S.; Takayanagi, H.; Yokochi, T.; Kayagaki, N.; Takeda, K.; Yagita, H.; Okumura, K.; Tanaka, N.; Taniguchi, T.; Ogasawara, K. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur. J. Immunol., 2001, 31, 3138-46.
91. Liang, X.; Liu, Y.; Zhang, Q.; Gao, L.; Han, L.; Ma, C.; Zhang, L.; Chen, Y. H.; Sun, W. Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J. Immunol., 2007, 178, 503-10.
92. Liu, Y. G.; Liu, S. X.; Liang, X. H.; Zhang, Q.; Gao, L. F.; Han, L. H.; Cao, Y. L.; Hou, N.; Du, J.; Sun, W. S. Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model. Biochem. Biophys. Res. Commun., 2007, 352, 329-34.
93. Ghavami, S.; Hashemi, M.; Kadkhoda, K.; Alavian, S. M.; Bay, G. H.; Los, M. Apoptosis in liver diseases - detection and therapeutic applications. Med. Sci. Monit., 2005, 11, RA337-45.
94. Kotelkin, A.; Prikhod'ko, E. A.; Cohen, J. I.; Collins, P. L.; Bukreyev, A. Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J. Virol., 2003, 77, 9156-72.
95. Clarke, P.; Meintzer, S. M.; Gibson, S.; Widmann, C.; Garrington, T. P.; Johnson, G. L.; Tyler, K. L. Reovirus-induced apoptosis is mediated by TRAIL. J. Virol., 2000, 74, 8135-9.
96. Liu, J. M.; Zhu, Y.; Xu, Z. W.; Ouyang, W. M.; Wang, J. P.; Liu, X. S.; Cao, Y. X.; Li, Q.; Fang, L.; Zhuang, R.; Yang, A. G.; Jin, B. Q. Dynamic changes of apoptosis-inducing ligands and Th1/Th2 like subpopulations in Hantaan virus-induced hemorrhagic fever with renal syndrome. Clin. Immunol., 2006, 119, 245-51.
97. Routes, J. M.; Ryan, S.; Clase, A.; Miura, T.; Kuhl, A.; Potter, T. A.; Cook, J. L. Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J. Immunol., 2000, 165, 4522-7.
98. Basile, J. R.; Zacny, V.; Munger, K. The cytokines tumor necrosis factor-alpha (TNF-alpha) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J. Biol. Chem., 2001, 276, 22522-8.
99. Rivera-Walsh, I.; Waterfield, M.; Xiao, G.; Fong, A.; Sun, S. C. NF-kappaB signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I Tax-induced T-cell death. J. Biol. Chem., 2001, 276, 40385-8.
100. Wurzer, W. J.; Ehrhardt, C.; Pleschka, S.; Berberich-Siebelt, F.; Wolff, T.; Walczak, H.; Planz, O.; Ludwig, S. NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/ FasL is crucial for efficient influenza virus propagation. J. Biol. Chem., 2004, 279, 30931-7.
101. Raftery, M. J.; Schwab, M.; Eibert, S. M.; Samstag, Y.; Walczak, H.; Schonrich, G. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity, 2001, 15, 997-1009.
102. Vidalain, P. O.; Azocar, O.; Lamouille, B.; Astier, A.; Rabourdin-Combe, C.; Servet-Delprat, C. Measles virus induces functional TRAIL production by human dendritic cells. J. Virol., 2000, 74, 556-9.
103. Okada, H.; Kobune, F.; Sato, T. A.; Kohama, T.; Takeuchi, Y.; Abe, T.; Takayama, N.; Tsuchiya, T.; Tashiro, M. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients. Arch. Virol., 2000, 145, 905-20.
104. Vidalain, P. O.; Azocar, O.; Rabourdin-Combe, C.; Servet-Delprat, C. Measle virus-infected dendritic cells develop immunosuppressive and cytotoxic activities. Immunobiology, 2001, 204, 629-38.
105. Schneider-Schaulies, S.; Klagge, I. M.; ter Meulen, V. Dendritic cells and measles virus infection. Curr. Top. Microbiol. Immunol., 2003, 276, 77-101.
106. Roe, M. F.; Bloxham, D. M.; White, D. K.; Ross-Russell, R. I.; Tasker, R. T.; O'Donnell, D. R. Lymphocyte apoptosis in acute respiratory syncytial virus bronchiolitis. Clin. Exp. Immunol., 2004, 137, 139-45.
107. Gupta, M.; Spiropoulou, C.; Rollin, P. E. Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virology, 2007, 364, 45-54.
108. Hensley, L. E.; Young, H. A.; Jahrling, P. B.; Geisbert, T. W. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett., 2002, 80, 169-79.
109. Lum, J. J.; Schnepple, D. J.; Badley, A. D. Acquired T-cell sensitivity to TRAIL mediated killing during HIV infection is regulated by CXCR4-gp120 interactions. AIDS, 2005, 19, 1125-33.
110. Herbeuval, J. P.; Boasso, A.; Grivel, J. C.; Hardy, A. W.; Anderson, S. A.; Dolan, M. J.; Chougnet, C.; Lifson, J. D.; Shearer, G. M. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood, 2005, 105, 2458-64.
111. Hansjee, N.; Kaufmann, G. R.; Strub, C.; Weber, R.; Battegay, M.; Erb, P. Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes. J. Acquir. Immune Defic. Syndr., 2004, 36, 671-7.
112. Lichtner, M.; Maranon, C.; Vidalain, P. O.; Azocar, O.; Hanau, D.; Lebon, P.; Burgard, M.; Rouzioux, C.; Vullo, V.; Yagita, H.; Rabourdin-Combe, C.; Servet, C.; Hosmalin, A. HIV type 1-infected dendritic cells induce apoptotic death in infected and uninfected primary CD4 T lymphocytes. AIDS Res. Hum. Retroviruses, 2004, 20, 175-82.
113. Katsikis, P. D.; Garcia-Ojeda, M. E.; Torres-Roca, J. F.; Tijoe, I. M.; Smith, C. A.; Herzenberg, L. A.; Herzenberg, L. A. Interleukin-1 beta converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J. Exp. Med., 1997, 186, 1365-72.
114. Lum, J. J.; Pilon, A. A.; Sanchez-Dardon, J.; Phenix, B. N.; Kim, J. E.; Mihowich, J.; Jamison, K.; Hawley-Foss, N.; Lynch, D. H.; Badley, A. D. Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J. Virol., 2001, 75, 11128-36.
115. Miura, Y.; Misawa, N.; Maeda, N.; Inagaki, Y.; Tanaka, Y.; Ito, M.; Kayagaki, N.; Yamamoto, N.; Yagita, H.; Mizusawa, H.; Koyanagi, Y. Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J. Exp. Med., 2001, 193, 651-60.
116. Zhang, M.; Li, X.; Pang, X.; Ding, L.; Wood, O.; Clouse, K.; Hewlett, I.; Dayton, A. I. Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat. J. Biomed. Sci., 2001, 8, 290-6.
117. Rossio, J. L.; Esser, M. T.; Suryanarayana, K.; Schneider, D. K.; Bess, J. W., Jr.; Vasquez, G. M.; Wiltrout, T. A.; Chertova, E.; Grimes, M. K.; Sattentau, Q.; Arthur, L. O.; Henderson, L. E.; Lifson, J. D. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol., 1998, 72, 7992-8001.
118. Herbeuval, J. P.; Hardy, A. W.; Boasso, A.; Anderson, S. A.; Dolan, M. J.; Dy, M.; Shearer, G. M. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. USA, 2005, 102, 13974-9.
119. Dimitrov, D. S.; Willey, R. L.; Sato, H.; Chang, L. J.; Blumenthal, R.; Martin, M. A. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol., 1993, 67, 2182-90.
120. Piatak, M., Jr.; Saag, M. S.; Yang, L. C.; Clark, S. J.; Kappes, J. C.; Luk, K. C.; Hahn, B. H.; Shaw, G. M.; Lifson, J. D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science, 1993, 259, 1749-54.
121. Finkel, T. H.; Tudor-Williams, G.; Banda, N. K.; Cotton, M. F.; Curiel, T.; Monks, C.; Baba, T. W.; Ruprecht, R. M.; Kupfer, A. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat. Med., 1995, 1, 129-34.
122. Schnittman, S. M.; Psallidopoulos, M. C.; Lane, H. C.; Thompson, L.; Baseler, M.; Massari, F.; Fox, C. H.; Salzman, N. P.; Fauci, A. S. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science, 1989, 245, 305-8.
123. Siegal, F. P.; Kadowaki, N.; Shodell, M.; Fitzgerald-Bocarsly, P. A.; Shah, K.; Ho, S.; Antonenko, S.; Liu, Y. J. The nature of the principal type 1 interferon-producing cells in human blood. Science, 1999, 284, 1835-7.
124. Herbeuval, J. P.; Nilsson, J.; Boasso, A.; Hardy, A. W.; Kruhlak, M. J.; Anderson, S. A.; Dolan, M. J.; Dy, M.; Andersson, J.; Shearer, G. M. Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc. Natl. Acad. Sci. USA, 2006, 103, 7000-5.
125. Herbeuval, J. P.; Shearer, G. M. HIV-1 immunopathogenesis: how good interferon turns bad. Clin. Immunol., 2007, 123, 121-8.
126. Gibellini, D.; Re, M. C.; Ponti, C.; Vitone, F.; Bon, I.; Fabbri, G.; Grazia Di Iasio, M.; Zauli, G. HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: a potential molecular mechanism to escape TRAIL cytotoxicity. J. Cell. Physiol., 2005, 203, 547-56.
127. Zheng, L.; Yang, Y.; Guocai, L.; Pauza, C. D.; Salvato, M. S. HIV Tat protein increases Bcl-2 expression in monocytes which inhibits monocyte apoptosis induced by tumor necrosis factor-alpha-related apoptosis-induced ligand. Intervirology, 2007, 50, 224-8.
128. Audige, A.; Urosevic, M.; Schlaepfer, E.; Walker, R.; Powell, D.; Hallenberger, S.; Joller, H.; Simon, H. U.; Dummer, R.; Speck, R. F. Anti-HIV state but not apoptosis depends on IFN signature in CD4+ T cells. J. Immunol., 2006, 177, 6227-37.
129. Swingler, S.; Mann, A. M.; Zhou, J.; Swingler, C.; Stevenson, M. Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog., 2007, 3, 1281-90.
130. Herbeuval, J. P.; Grivel, J. C.; Boasso, A.; Hardy, A. W.; Chougnet, C.; Dolan, M. J.; Yagita, H.; Lifson, J. D.; Shearer, G. M. CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood, 2005, 106, 3524-31.
131. Secchiero, P.; Mirandola, P.; Zella, D.; Celeghini, C.; Gonelli, A.; Vitale, M.; Capitani, S.; Zauli, G. Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4(+) T cells. Blood, 2001, 98, 2474-81.
132. Kawanishi, M.; Tada-Oikawa, S.; Kawanishi, S. Epstein-Barr virus BHRF1 functions downstream of Bid cleavage and upstream of mitochondrial dysfunction to inhibit TRAIL-induced apoptosis in BJAB cells. Biochem. Biophys. Res. Commun., 2002, 297, 682-7.
133. Snow, A. L.; Vaysberg, M.; Krams, S. M.; Martinez, O. M. EBV B lymphoma cell lines from patients with post-transplant lymphoproliferative disease are resistant to TRAIL-induced apoptosis. Am. J. Transplant., 2006, 6, 976-85.
134. Snow, A. L.; Lambert, S. L.; Natkunam, Y.; Esquivel, C. O.; Krams, S. M.; Martinez, O. M. EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J. Immunol., 2006, 177, 3283-93.
135. Benedict, C. A.; Norris, P. S.; Prigozy, T. I.; Bodmer, J. L.; Mahr, J. A.; Garnett, C. T.; Martinon, F.; Tschopp, J.; Gooding, L. R.; Ware, C. F. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J. Biol. Chem., 2001, 276, 3270-8.
136. Lichtenstein, D. L.; Doronin, K.; Toth, K.; Kuppuswamy, M.; Wold, W. S.; Tollefson, A. E. Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2. J. Virol., 2004, 78, 12297-307.
137. Burgert, H. G.; Ruzsics, Z.; Obermeier, S.; Hilgendorf, A.; Windheim, M.; Elsing, A. Subversion of host defense mechanisms by adenoviruses. Curr. Top. Microbiol. Immunol., 2002, 269, 273-318.
138. Moise, A. R.; Grant, J. R.; Vitalis, T. Z.; Jefferies, W. A. Adenovirus E3-6.7K maintains calcium homeostasis and prevents apoptosis and arachidonic acid release. J. Virol., 2002, 76, 1578-87.
139. Lub-de Hooge, M. N.; de Jong, S.; Vermot-Desroches, C.; Tulleken, J. E.; de Vries, E. G.; Zijlstra, J. G. Endotoxin increases plasma soluble tumor necrosis factor-related apoptosis-inducing ligand level mediated by the p38 mitogen-activated protein kinase signaling pathway. Shock, 2004, 22, 186-8.
140. Zheng, S. J.; Jiang, J.; Shen, H.; Chen, Y. H. Reduced apoptosis and ameliorated listeriosis in TRAIL-null mice. J. Immunol., 2004, 173, 5652-8.
141. Lee, J.; Hampl, M.; Albert, P.; Fine, H. A. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia, 2002, 4, 312-23.
142. Lin, T.; Gu, J.; Zhang, L.; Huang, X.; Stephens, L. C.; Curley, S. A.; Fang, B. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res., 2002, 62, 3620-5.
143. Ma, H.; Liu, Y.; Liu, S.; Xu, R.; Zheng, D. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology, 2005, 42, 1355-63.
144. Kelley, S. K.; Harris, L. A.; Xie, D.; Deforge, L.; Totpal, K.; Bussiere, J.; Fox, J. A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther., 2001, 299, 31-8.
145. Naka, T.; Sugamura, K.; Hylander, B. L.; Widmer, M. B.; Rustum, Y. M.; Repasky, E. A. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res., 2002, 62, 5800-6.
146. Hylander, B. L.; Pitoniak, R.; Penetrante, R. B.; Gibbs, J. F.; Oktay, D.; Cheng, J.; Repasky, E. A. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J. Transl. Med., 2005, 3, 22.
147. Tanaka, S.; Sugimachi, K.; Shirabe, K.; Shimada, M.; Wands, J. R. Expression and antitumor effects of TRAIL in human cholangiocarcinoma. Hepatology, 2000, 32, 523-7.
148. Mitsiades, C. S.; Treon, S. P.; Mitsiades, N.; Shima, Y.; Richardson, P.; Schlossman, R.; Hideshima, T.; Anderson, K. C. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood, 2001, 98, 795-804.
149. Roth, W.; Isenmann, S.; Naumann, U.; Kugler, S.; Bahr, M.; Dichgans, J.; Ashkenazi, A.; Weller, M. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem. Biophys. Res. Commun., 1999, 265, 479-83.
150. Pollack, I. F.; Erff, M.; Ashkenazi, A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin. Cancer Res., 2001, 7, 1362-9.
151. Gores, G. J.; Kaufmann, S. H. Is TRAIL hepatotoxic? Hepatology, 2001, 34, 3-6.
152. Pitti, R. M.; Marsters, S. A.; Ruppert, S.; Donahue, C. J.; Moore, A.; Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 1996, 271, 12687-90.
153. Bodmer, J. L.; Meier, P.; Tschopp, J.; Schneider, P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J. Biol. Chem., 2000, 275, 20632-7.
154. Lawrence, D.; Shahrokh, Z.; Marsters, S.; Achilles, K.; Shih, D.; Mounho, B.; Hillan, K.; Totpal, K.; DeForge, L.; Schow, P.; Hooley, J.; Sherwood, S.; Pai, R.; Leung, S.; Khan, L.; Gliniak, B.; Bussiere, J.; Smith, C. A.; Strom, S. S.; Kelley, S.; Fox, J. A.; Thomas, D.; Ashkenazi, A. Differential hepatocyte toxicity of recombinant Apo2L/ TRAIL versions. Nat. Med., 2001, 7, 383-5.
155. Ashkenazi, A.; Pai, R. C.; Fong, S.; Leung, S.; Lawrence, D. A.; Marsters, S. A.; Blackie, C.; Chang, L.; McMurtrey, A. E.; Hebert, A.; DeForge, L.; Koumenis, I. L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z.; Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest., 1999, 104, 155-62.
156. Schneider, P. Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. Methods Enzymol., 2000, 322, 325-45.
157. Ganten, T. M.; Koschny, R.; Sykora, J.; Schulze-Bergkamen, H.; Buchler, P.; Haas, T. L.; Schader, M. B.; Untergasser, A.; Stremmel, W.; Walczak, H. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin. Cancer Res., 2006, 12, 2640-6.
158. MacFarlane, M.; Kohlhaas, S. L.; Sutcliffe, M. J.; Dyer, M. J.; Cohen, G. M. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res., 2005, 65, 11265-70.
159. Hymowitz, S. G.; O'Connell, M. P.; Ultsch, M. H.; Hurst, A.; Totpal, K.; Ashkenazi, A.; de Vos, A. M.; Kelley, R. F. A unique zincbinding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/ TRAIL. Biochemistry, 2000, 39, 633-40.
160. Tolcher, A. W.; Mita, M.; Meropol, N. J.; von Mehren, M.; Patnaik, A.; Padavic, K.; Hill, M.; Mays, T.; McCoy, T.; Fox, N. L.; Halpern, W.; Corey, A.; Cohen, R. B. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol., 2007, 25, 1390-5.
161. Pukac, L.; Kanakaraj, P.; Humphreys, R.; Alderson, R.; Bloom, M.; Sung, C.; Riccobene, T.; Johnson, R.; Fiscella, M.; Mahoney, A.; Carrell, J.; Boyd, E.; Yao, X. T.; Zhang, L.; Zhong, L.; von Kerczek, A.; Shepard, L.; Vaughan, T.; Edwards, B.; Dobson, C.; Salcedo, T.; Albert, V. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer, 2005, 92, 1430-41.
162. Georgakis, G. V.; Li, Y.; Humphreys, R.; Andreeff, M.; O'Brien, S.; Younes, M.; Carbone, A.; Albert, V.; Younes, A. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br. J. Haematol., 2005, 130, 501-10.
163. Motoki, K.; Mori, E.; Matsumoto, A.; Thomas, M.; Tomura, T.; Humphreys, R.; Albert, V.; Muto, M.; Yoshida, H.; Aoki, M.; Tamada, T.; Kuroki, R.; Yoshida, H.; Ishida, I.; Ware, C. F.; Kataoka, S. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin. Cancer Res., 2005, 11, 3126-35.
164. Garber, K. New apoptosis drugs face critical test. Nat. Biotechnol., 2005, 23, 409-11.
165. Takeda, K.; Yamaguchi, N.; Akiba, H.; Kojima, Y.; Hayakawa, Y.; Tanner, J. E.; Sayers, T. J.; Seki, N.; Okumura, K.; Yagita, H.; Smyth, M. J. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med., 2004, 199, 437-48.
166. Uno, T.; Takeda, K.; Kojima, Y.; Yoshizawa, H.; Akiba, H.; Mittler, R. S.; Gejyo, F.; Okumura, K.; Yagita, H.; Smyth, M. J. Eradication of established tumors in mice by a combination antibodybased therapy. Nat. Med., 2006, 12, 693-8.
167. Lum, J. J.; Schnepple, D. J.; Nie, Z.; Sanchez-Dardon, J.; Mbisa, G. L.; Mihowich, J.; Hawley, N.; Narayan, S.; Kim, J. E.; Lynch, D. H.; Badley, A. D. Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity. J. Virol., 2004, 78, 6033-42.
168. Schilling, P. J.; Murray, J. L.; Markowitz, A. B. Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction. Cancer 1992, 69, 256-60.
169. Ogasawara, J.; Watanabe-Fukunaga, R.; Adachi, M.; Matsuzawa, A.; Kasugai, T.; Kitamura, Y.; Itoh, N.; Suda, T.; Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature, 1993, 364, 806-9.
170. Hao, C.; Song, J. H.; Hsi, B.; Lewis, J.; Song, D. K.; Petruk, K. C.; Tyrrell, D. L.; Kneteman, N. M. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res., 2004, 64, 8502-6.
171. Qin, J.; Chaturvedi, V.; Bonish, B.; Nickoloff, B. J. Avoiding premature apoptosis of normal epidermal cells. Nat. Med., 2001, 7, 385-6.
172. Qin, J. Z.; Bacon, P. E.; Chaturvedi, V.; Bonish, B.; Nickoloff, B. J. Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations. Exp. Dermatol., 2002, 11, 573-83.
173. Dorr, J.; Roth, K.; Zurbuchen, U.; Deisz, R.; Bechmann, I.; Lehmann, T. N.; Meier, S.; Nitsch, R.; Zipp, F. Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate. J. Neuroimmunol., 2005, 167, 204-9.
174. Kim, S. H.; Kim, K.; Kwagh, J. G.; Dicker, D. T.; Herlyn, M.; Rustgi, A. K.; Chen, Y.; El-Deiry, W. S. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J. Biol. Chem., 2004, 279, 40044-52.
175. Sayers, T. J.; Murphy, W. J. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol. Immunother., 2006, 55, 76-84.
176. Hao, C.; Beguinot, F.; Condorelli, G.; Trencia, A.; Van Meir, E. G.; Yong, V. W.; Parney, I. F.; Roa, W. H.; Petruk, K. C. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res., 2001, 61, 1162-70.
177. Song, J. H.; Bellail, A.; Tse, M. C.; Yong, V. W.; Hao, C. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J. Neurosci., 2006, 26, 3299-308.
178. Ehrhardt, H.; Fulda, S.; Schmid, I.; Hiscott, J.; Debatin, K. M.; Jeremias, I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene, 2003, 22, 3842-52.
179. Malhi, H.; Gores, G. J. TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene, 2006, 25, 7333-5.
180. Secchiero, P.; Zerbinati, C.; Rimondi, E.; Corallini, F.; Milani, D.; Grill, V.; Forti, G.; Capitani, S.; Zauli, G. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell. Mol. Life Sci., 2004, 61, 1965-74.
181. Secchiero, P.; Gonelli, A.; Carnevale, E.; Milani, D.; Pandolfi, A.; Zella, D.; Zauli, G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation, 2003, 107, 2250-6.